Candida auris has developed as a multidrug-resistant (MDR) fungal pathogen connected to medical care around the world. Due to its outbreak potential, antibiotic resistance, and high mortality, Candida auris infection has arisen as a significant problem in the care of patients admitted to ICUs in India. Candidemia caused by C. auris has been recorded from three continents since the initial report of earcanal infection by this yeast in Japan in 2009, with a substantial number of cases from India. Some C. auris strains have higher minimum inhibitory concentrations (MICs) than amphotericin B and echinocandin compounds, while some C. auris strains are resistant to all antifungal medication classes. According to a comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) techniques, C. auris isolates exhibit strikingly comparable fluconazole resistance but a broad range of MICs for the other antifungal drug classes. The goal of this research is to learn more about curcumin's antifungal properties. This polyphenolic chemical has been used for medical, culinary, and other uses throughout Asia for centuries. Although curcumin has been shown to have antifungal properties, a current study reveals that curcumin works by disrupting the fungal cell wall.